Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 3/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | MAP3K8 | P41279 | 8/20 | 0.37 |
| ▸ | EGFR | P00533 | 8/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.35 |
| ▸ | SRC | P12931 | 3/20 | 0.35 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.35 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.35 |
| ▸ | PRKACA | P17612 | 2/20 | 0.34 |
| ▸ | PRKACG | P22612 | 2/20 | 0.34 |
| ▸ | PRKACB | P22694 | 2/20 | 0.34 |
| ▸ | IKBKB | O14920 | 1/20 | 0.34 |
| ▸ | MMP3 | P08254 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | PRKCA | P17252 | 1/20 | 0.34 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19889983 | 0.89 | CYP11B2 (0.38) | CYP11B2CYP11B1SLC6A3MAP3K8EGFR | |
| SCHEMBL19877781 | 0.82 | CYP11B2 (0.41) | CYP11B2CYP11B1SLC6A3MAP3K8EGFR | |
| SCHEMBL19889981 | 0.82 | SLC6A3 (0.41) | SLC6A3EGFR | |
| SCHEMBL19877026 | 0.80 | CYP11B2 (0.36) | CYP11B2CYP11B1SLC6A3MAP3K8EGFR | |
| SCHEMBL19889984 | 0.77 | AR (0.38) | CYP11B2MAP3K8EGFRERBB2 | |
| SCHEMBL19877059 | 0.76 | SRC (0.41) | SLC6A3MAP3K8EGFRERBB2SRC | |
| SCHEMBL19889982 | 0.75 | KHK (0.36) | CYP11B2CYP11B1SLC6A3MAP3K8EGFR | |
| SCHEMBL5257280 | 0.74 | KMT2A (0.47) | CSNK1A1CLK4CYP3A4 | |
| SCHEMBL19889931 | 0.74 | SLC22A12 (0.33) | CYP11B2SLC6A3MAP3K8EGFRERBB2 | |
| SCHEMBL19877263 | 0.73 | CYP11B2 (0.35) | CYP11B2CYP11B1MAP3K8EGFRERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3496716-B1 | COMPOUNDS USEFUL FOR ALTERING THE LEVELS OF BILE ACIDS FOR THE TREATMENT OF DIABETES AND CARDIOMETABOLIC DISEASE | MERCK SHARP & DOHME (US) | 2021-11-03 | — | — | EP | disclosed |
| EP-3496716-B1 | COMPOUNDS USEFUL FOR ALTERING THE LEVELS OF BILE ACIDS FOR THE TREATMENT OF DIABETES AND CARDIOMETABOLIC DISEASE | MERCK SHARP & DOHME (US) | 2021-11-03 | — | — | EP | disclosed |
| US-10414774-B2 | Compound useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolc disease | MERCK SHARP & DOHME CORP. (US) | 2019-09-17 | — | — | US | disclosed |
| US-10414774-B2 | Compound useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolc disease | MERCK SHARP & DOHME CORP. (US) | 2019-09-17 | — | — | US | disclosed |
| US-20190218223-A1 | COMPOUNDS USEFUL FOR ALTERING THE LEVELS OF BILE ACIDS FOR THE TREATMENT OF DIABETES AND CARDIOMETABOLC DISEASE | MERCK SHARP & DOHME CORP. (US) | 2019-07-18 | — | — | US | disclosed |
| US-20190218223-A1 | COMPOUNDS USEFUL FOR ALTERING THE LEVELS OF BILE ACIDS FOR THE TREATMENT OF DIABETES AND CARDIOMETABOLC DISEASE | MERCK SHARP & DOHME CORP. (US) | 2019-07-18 | — | — | US | disclosed |
| WO-2018034918-A1 | COMPOUNDS USEFUL FOR ALTERING THE LEVELS OF BILE ACIDS FOR THE TREATMENT OF DIABETES AND CARDIOMETABOLIC DISEASE | MERCK SHARP & DOHME CORP. (US) | 2018-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190218223-A1 | COMPOUNDS USEFUL FOR ALTERING THE LEVELS OF BILE ACIDS FOR THE TREATMENT OF DIABETES AND CARDIOMETABOLC DISEASE | CYP27A1, CYP7B1, CYP7A1 | CYP11B2 8/4885CYP11B1 5/4885SLC6A3 1421/4885 |
| US-10414774-B2 | Compound useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolc disease | CYP27A1, CYP7B1, SLC10A1 | CYP11B2 8/4885CYP11B1 6/4885SLC6A3 1509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.